1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6211)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13088)
  2. Department of Medicine (13004)
  3. Center for Hematologic Malignancies (10395)
  4. GSK Faculty (4422)
  5. Adult Leukemia (3583)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (775)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (204)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (431)

More Publishers

Results (13088)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Primary overall survival (OS) analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in relapsed/refractory large B-cell lymphoma (R/R LBCL)
    Meeting Abstract

    Dreger, P.; Westin, J.; Oluwole, O.; Kersten, M. J.; Miklos, D.; Perales, M. A.; Ghobadi, A.; Rapoport, A.; Sureda, A.; Jacobson, C.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Epidemiological impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) use in previously untreated diffuse large B-cell lymphoma (DLBCL) on second line (2L) treatment: An ad hoc analysis from POLARIX study
    Meeting Abstract

    Oellerich, T.; Boissard, F.; Tilly, H.; Lenz, G.; Collins, G. P.; Pinto, A.; Sehn, L. H.; Salles, G.; Roussel, M.; Simonella, L.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study
    Meeting Abstract

    Dietrich, S.; Bartlett, N. L.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Fay, K.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Assessing the burden of adverse events in a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Stilgenbauer, S.; Seymour, J. F.; Byrd, J. C.; Munir, T.; Ghia, P.; Kater, A. P.; Chanan-Khan, A.; Furman, R. R.; O'Brien, S. M.; Brown, J. R.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L-MIND study
    Meeting Abstract

    Düll, J.; Abrisqueta, P.; Andre, M.; Augustin, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Kalakonda, N.; Liberati, A. M.; Maddocks, K. J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Subgroup analyses of primary refractory vs early relapsed large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy
    Meeting Abstract

    Glass, B.; Nastoupil, L.; Kamdar, M.; Chavez, J. C.; Ghesquieres, H.; Ghosh, M.; Holmes, H.; López-Guillermo, A.; Martínez-López, J.; Novak, U.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in pts with relapsed/ refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies
    Meeting Abstract

    Raab, M. S.; Hanel, M.; Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maisel, C.; Arnulf, B.; Larson, S. M.; Varshavsky-Yanovsky, A. N.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHL): Updated results from a phase I/II study
    Meeting Abstract

    von Tresckow, B.; Budde, L. E.; Bartlett, N. L.; Giri, P.; Schuster, S. J.; Assouline, S.; Yoon, S. S.; Fay, K.; Matasar, M.; Gutierrez, N. C.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Glofitamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study
    Meeting Abstract

    Dietrich, S.; Falchi, L.; Carlo-Stella, C.; Morschhauser, F.; Hutchings, M.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez-Lopez, J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • PRIMA/ENGOT-OV26/GOG-3012 study: Long-term conditional progression-free survival (cPFS)
    Meeting Abstract

    Braicu, E.; González-Martín, A.; Pothuri, B.; Vergote, I.; Graybill, W.; Mirza, M. R.; McCormick, C.; Lorusso, D.; Freyer, G.; Backes, F. J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save